[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2017005715A - Potentes moduladores de gamma-secretasa. - Google Patents

Potentes moduladores de gamma-secretasa.

Info

Publication number
MX2017005715A
MX2017005715A MX2017005715A MX2017005715A MX2017005715A MX 2017005715 A MX2017005715 A MX 2017005715A MX 2017005715 A MX2017005715 A MX 2017005715A MX 2017005715 A MX2017005715 A MX 2017005715A MX 2017005715 A MX2017005715 A MX 2017005715A
Authority
MX
Mexico
Prior art keywords
secretase modulators
potent gamma
potent
gamma
secretase
Prior art date
Application number
MX2017005715A
Other languages
English (en)
Other versions
MX381224B (es
Inventor
L Wagner Steven
C Mobley William
E Tanzi Rudolph
Johnson Graham
Buckle Ronald
MAYHEW Nicholas
Jason Herr Robert
D Rynearson Kevin
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of MX2017005715A publication Critical patent/MX2017005715A/es
Publication of MX381224B publication Critical patent/MX381224B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente compuestos y métodos para tratar un trastorno asociado con niveles aberrantes de péptido Aß, incluyendo enfermedad de Alzheimer.
MX2017005715A 2014-10-31 2015-10-30 Potentes moduladores de gamma-secretasa. MX381224B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462073553P 2014-10-31 2014-10-31
PCT/US2015/058429 WO2016070107A1 (en) 2014-10-31 2015-10-30 Potent gamma-secretase modulators

Publications (2)

Publication Number Publication Date
MX2017005715A true MX2017005715A (es) 2018-02-23
MX381224B MX381224B (es) 2025-03-12

Family

ID=55858421

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005715A MX381224B (es) 2014-10-31 2015-10-30 Potentes moduladores de gamma-secretasa.

Country Status (8)

Country Link
US (2) US10472346B2 (es)
EP (1) EP3212633B1 (es)
JP (1) JP6672296B2 (es)
CN (1) CN107406423B (es)
AU (1) AU2015338946B2 (es)
CA (1) CA2966423C (es)
MX (1) MX381224B (es)
WO (1) WO2016070107A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2966423C (en) 2014-10-31 2023-10-24 The General Hospital Corporation Potent gamma-secretase modulators
CA3085366A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
AU2019294482B2 (en) 2018-06-27 2022-09-01 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
IL295953A (en) * 2020-02-28 2022-10-01 Remix Therapeutics Inc Pyridazine derivatives regulate nucleic acid splicing
WO2023034827A1 (en) * 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
AU730850B2 (en) 1997-10-28 2001-03-15 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
AU2003259965A1 (en) 2002-08-20 2004-03-11 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
US7244739B2 (en) 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
DE602005014274D1 (de) 2004-12-09 2009-06-10 Hoffmann La Roche Phenylpiperazin-methanon-derivate
TW200736252A (en) 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
KR20090007347A (ko) 2006-03-22 2009-01-16 버텍스 파마슈티칼스 인코포레이티드 증식성 장애의 치료를 위한 ｃ-ＭＥＴ 단백질 키나제 억제제
US8551995B2 (en) 2007-01-19 2013-10-08 Xcovery Holding Company, Llc Kinase inhibitor compounds
EP2131654A4 (en) 2007-03-02 2011-02-02 Merck Sharp & Dohme Bipyridine-carboxamide-orexin receptor Antagonist
GB0720444D0 (en) * 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
US20110118236A1 (en) 2008-03-25 2011-05-19 Michiyo Mochizuki Heterocyclic compound
CA2753696A1 (en) 2009-02-26 2010-09-02 Noritaka Kitazawa Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051807A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012180281A (ja) 2009-06-29 2012-09-20 Dainippon Sumitomo Pharma Co Ltd 新規オキサジアゾール誘導体
EP2454239B1 (en) 2009-07-15 2014-08-13 Janssen Pharmaceuticals Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
JP2013028538A (ja) 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
WO2011120026A1 (en) 2010-03-26 2011-09-29 Glaxo Group Limited Pyrazolyl-pyrimidines as kinase inhibitors
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9403815B2 (en) 2010-06-24 2016-08-02 The Regents Of The University Of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
US9938263B2 (en) 2013-03-12 2018-04-10 The General Hospital Corporation Gamma-secretase modulators
CA2966423C (en) 2014-10-31 2023-10-24 The General Hospital Corporation Potent gamma-secretase modulators

Also Published As

Publication number Publication date
AU2015338946A1 (en) 2017-06-15
US10472346B2 (en) 2019-11-12
MX381224B (es) 2025-03-12
EP3212633A4 (en) 2018-07-25
AU2015338946B2 (en) 2020-06-11
JP2017533237A (ja) 2017-11-09
CA2966423C (en) 2023-10-24
US20180093967A1 (en) 2018-04-05
US11117884B2 (en) 2021-09-14
WO2016070107A1 (en) 2016-05-06
CA2966423A1 (en) 2016-05-06
US20200055840A1 (en) 2020-02-20
CN107406423B (zh) 2020-06-16
JP6672296B2 (ja) 2020-03-25
EP3212633B1 (en) 2019-12-04
CN107406423A (zh) 2017-11-28
EP3212633A1 (en) 2017-09-06
BR112017009010A2 (pt) 2017-12-26

Similar Documents

Publication Publication Date Title
MX2017005715A (es) Potentes moduladores de gamma-secretasa.
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MX380263B (es) Procesos para producir brivaracetam.
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
HUE049014T2 (hu) Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
MX2020004073A (es) Procesos de siembra en serie y usos de los mismos.
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
IL248668A0 (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
DK3463351T3 (da) Behandling til parkinsons sygdom
MX2017006692A (es) Trastornos neurodegenerativos.
ZA201805545B (en) Oromucosal nanofiber carriers for therapeutic treatment
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
MX392383B (es) Metodos para tratar afecciones oculares.
GB201612165D0 (en) Combinations for the treatment of type 2 diabetes
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
MX2017011454A (es) Procesos para preparar fluorocetólidos.
GB201807612D0 (en) Structured file encryption process
DK3449465T3 (da) Nethindebilledbehandling
PH12019501678A1 (en) Potassium channel modulators
EP3730141A4 (en) THERAPEUTIC AGENT FOR NOCTURAL POLLAKIURIA
CO2018007236A2 (es) Reguladores cftr y métodos de uso
LT3119386T (lt) Kompozicija, skirta panaudoti su tarpslanksteliniais diskais susijusio skausmo gydymui
DK3506956T3 (da) Lægemiddel, særlig til behandling af fistler